| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
Loganin targets COX-1, TNF-α, Nrf2/HO-1 signaling, and β-secretase. It is an inhibitor of COX-1 and suppresses TNF-α formation. Loganin upregulates the Nrf2/HO-1 signaling pathway to exert anti-inflammatory and antioxidant effects. It also inhibits β-secretase, suggesting potential neuroprotective applications.
|
|---|---|
| ln Vitro |
Loganin demonstrates significant in vitro activity by reducing the production of NO, PGE2, TNF-α, and IL-1β at concentrations of 0-30 µM for 1 hour. It shows cytotoxicity to RAW264.7 macrophages at high concentrations (0-50 µM over 24 hours). Loganin has potent free-radical-scavenging activity and inhibitory effects on melanogenesis. It exhibits cytotoxic activity against Caco-2 cells (IC50 = 1.28 µg/mL by MTT assay) and COLO320 cells (IC50 = 1 µg/mL).
|
| ln Vivo |
In vivo, Loganin provides benefits for spinal muscular atrophy (SMA) therapeutics via improving SMN restoration, muscle strength, and body weight. In type 2 diabetes mice, loganin not only lowers blood glucose but also attenuates hyperglycemia-induced inflammation, oxidative stress, and apoptosis. It offers protective effects against acute lung injury and pulmonary fibrosis in animal models.
|
| Enzyme Assay |
In vitro enzyme assays for Loganin involve measuring COX-1 inhibition activity. The enzyme is incubated with arachidonic acid substrate and varying concentrations of Loganin. Prostaglandin production is measured using ELISA or other detection methods. IC50 values are determined from dose-response curves. β-secretase inhibition assays can also be performed using fluorogenic substrates.
|
| Cell Assay |
In vitro cellular assays for Loganin involve culturing RAW264.7 macrophages or Caco-2 cells. Cells are treated with Loganin at varying concentrations (typically 0-50 µM) for specified durations (1-24 hours). Nitric oxide production is measured using the Griess assay. Cytokine levels (TNF-α, IL-1β, PGE2) are measured by ELISA. Cell viability is assessed using MTT assays.
|
| Animal Protocol |
In vivo animal studies for Loganin have been conducted in mouse models of type 2 diabetes and spinal cord injury. The compound is typically administered orally or intraperitoneally. Blood glucose levels, inflammatory markers, and oxidative stress parameters are measured. In SMA models, muscle strength and body weight are assessed. Dosing regimens vary depending on the study objectives.
|
| ADME/Pharmacokinetics |
Loganin is soluble in DMSO, water, and 100% ethanol, but insoluble in ether, ethyl acetate, and acetone. It has a density of 1.5 g/cm³. The compound should be stored at -20°C for long-term stability. As a powder, it can be stored at -20°C for up to 3 years or at 4°C for up to 2 years. In solvent, it can be stored at -80°C for up to 2 years.
|
| Toxicity/Toxicokinetics |
Loganin is generally considered safe at research-relevant concentrations. Comprehensive toxicological data are limited. The compound is a natural product and is not known to be highly toxic. It is intended for research use only and is not approved for human therapeutic applications. Standard laboratory safety precautions should be taken when handling the compound.
|
| References |
|
| Additional Infomation |
Loganin is an iridoid monoterpene compound with the molecular formula C17H26O10, isolated from various plants, and possesses neuroprotective and anti-inflammatory properties. It is a plant metabolite with neuroprotective activity, and is also an inhibitor of EC 3.4.23.46 (membrane protease 2), EC 3.2.1.20 (α-glucosidase), an anti-inflammatory agent, and EC 3.1.1.7 (acetylcholinesterase). It is a cyclopentapyran compound, and also a β-D-glucoside, acrylate, monosaccharide derivative, iridoid monoterpene, methyl ester, and secondary alcohol. It is functionally related to loganin. Loganin has been reported in spruce, Dipsacus asper, and other organisms with available data. See also: Menyanthes trifoliata leaves (partial).
Loganin is an iridoid glycoside compound from Cornus officinalis with anti-inflammatory, antioxidant, and antitumor properties. It protects against acute lung injury and pulmonary fibrosis by upregulating Nrf2/HO-1 signaling. Loganin has been studied for its neuroprotective effects and potential in treating spinal cord injury, type 2 diabetes, and spinal muscular atrophy. It is not approved for clinical use and is available for research purposes only. |
| Molecular Formula |
C17H26O10
|
|---|---|
| Molecular Weight |
390.3823
|
| Exact Mass |
390.152
|
| CAS # |
18524-94-2
|
| PubChem CID |
87691
|
| Appearance |
White to off-white solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
608.8±55.0 °C at 760 mmHg
|
| Melting Point |
222°C
|
| Flash Point |
217.9±25.0 °C
|
| Vapour Pressure |
0.0±4.0 mmHg at 25°C
|
| Index of Refraction |
1.600
|
| LogP |
-2.73
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
27
|
| Complexity |
580
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
C[C@H]1[C@H](C[C@H]2[C@@H]1[C@@H](OC=C2C(=O)OC)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)O
|
| InChi Key |
AMBQHHVBBHTQBF-UOUCRYGSSA-N
|
| InChi Code |
InChI=1S/C17H26O10/c1-6-9(19)3-7-8(15(23)24-2)5-25-16(11(6)7)27-17-14(22)13(21)12(20)10(4-18)26-17/h5-7,9-14,16-22H,3-4H2,1-2H3/t6-,7+,9-,10+,11+,12+,13-,14+,16-,17-/m0/s1
|
| Chemical Name |
methyl (1S,4aS,6S,7R,7aS)-6-hydroxy-7-methyl-1-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,4a,5,6,7,7a-hexahydrocyclopenta[c]pyran-4-carboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~128.08 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.40 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.40 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.40 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5616 mL | 12.8080 mL | 25.6161 mL | |
| 5 mM | 0.5123 mL | 2.5616 mL | 5.1232 mL | |
| 10 mM | 0.2562 mL | 1.2808 mL | 2.5616 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT02413099 | Completed | Drug: KBMSI-2 | Erectile Dysfunction | Hyun Jun Park | 2012-02 | Phase 4 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
